Literature DB >> 9250163

Transforming growth factor-beta, transforming growth factor-beta receptor II, and p27Kip1 expression in nontumorous and neoplastic human pituitaries.

L Jin1, X Qian, E Kulig, N Sanno, B W Scheithauer, K Kovacs, W F Young, R V Lloyd.   

Abstract

Transforming growth factor (TGF)-beta has been implicated in the regulation of normal and neoplastic anterior pituitary cell function. TGF-beta regulates the expression of various proteins, including p27Kip1 (p27), a cell cycle inhibitory protein. We examined TGF-beta, TGF-beta type II receptor (TGF-beta-RII), and p27 expression in normal pituitaries, pituitary adenomas, and carcinomas to analyze the possible roles of these proteins in pituitary tumorigenesis. Normal pituitary, pituitary adenomas, and pituitary carcinomas all expressed TGF-beta and TGF-beta-RII immunoreactivity. Reverse transcription polymerase chain reaction analysis showed TGF-beta 1, -beta 2, and -beta 3 isoforms and TGF-beta-RII in normal pituitaries and pituitary adenomas. Pituitary adenomas cells cultured for 7 days in defined media showed a biphasic response to TGF-beta with significant inhibition of follicle-stimulating hormone secretion at higher concentrations (10(-9) mol/L) and stimulation of follicle-stimulating hormone secretion at lower concentrations (10(-13) mol/L) of TGF-beta 1 in gonadotroph adenomas. Immunohistochemical analysis for p27 protein expression showed the highest levels in nontumorous pituitaries with decreased immunoreactivity in adenomas and carcinomas. When nontumorous pituitaries and various adenomas were analyzed for p27 and specific hormone production, growth hormone, luteinizing hormone, and thyroid-stimulating hormone cells and tumors had the highest percentages of cells expressing p27, whereas adrenocorticotrophic hormone cells and tumors had the lowest percentages. Immunoblotting analysis showed that adrenocorticotrophic hormone adenomas also had the lowest levels of p27 protein. Semiquantitative reverse transcription polymerase chain reaction and Northern hybridization analysis did not show significant differences in p27 mRNA expression in the various types of adenomas or in nontumorous pituitaries. In situ hybridization for p27 mRNA showed similar distributions of the gene product in nontumorous pituitaries, pituitary adenomas, and carcinomas. These results indicate that TGF-beta and TGF-beta-RII are widely expressed in nontumorous pituitaries and in pituitary neoplasms and that TGF-beta 1 regulates pituitary hormone secretion. The levels of the TGF-beta-regulated protein p27 decreases in the progression of normal to neoplastic pituitaries. In contrast, the mRNA levels of p27 remained relatively constant in nontumorous pituitaries, pituitary adenomas, and carcinomas, indicating that p27 protein levels in adenomas and carcinomas are regulated by translational and post-translational mechanisms.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9250163      PMCID: PMC1858020     

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  42 in total

1.  Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents.

Authors:  B St Croix; V A Flørenes; J W Rak; M Flanagan; N Bhattacharya; J M Slingerland; R S Kerbel
Journal:  Nat Med       Date:  1996-11       Impact factor: 53.440

2.  p27Kip1, a cyclin-Cdk inhibitor, links transforming growth factor-beta and contact inhibition to cell cycle arrest.

Authors:  K Polyak; J Y Kato; M J Solomon; C J Sherr; J Massague; J M Roberts; A Koff
Journal:  Genes Dev       Date:  1994-01       Impact factor: 11.361

3.  Differentiation of human pituitary adenomas determines the pattern of chromogranin/secretogranin messenger ribonucleic acid expression.

Authors:  L Jin; W F Chandler; J B Smart; B G England; R V Lloyd
Journal:  J Clin Endocrinol Metab       Date:  1993-03       Impact factor: 5.958

4.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

5.  Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors.

Authors:  K Nakayama; N Ishida; M Shirane; A Inomata; T Inoue; N Shishido; I Horii; D Y Loh; K Nakayama
Journal:  Cell       Date:  1996-05-31       Impact factor: 41.582

6.  Transforming growth factor beta 1-like immunoreactivity in the pituitary gland of the rat: effect of estrogen.

Authors:  G Burns; D K Sarkar
Journal:  Endocrinology       Date:  1993-09       Impact factor: 4.736

7.  Inhibition of prolactin gene transcription by transforming growth factor-beta in GH3 cells.

Authors:  B C Delidow; W M Billis; P Agarwal; B A White
Journal:  Mol Endocrinol       Date:  1991-11

8.  Expression and Regulation of Transforming Growth Factor B1 in Cultured Normal and Neoplastic Rat Pituitary Cells.

Authors:  Xiang Qian; Long Jin; Ricardo V. Lloyd
Journal:  Endocr Pathol       Date:  1996       Impact factor: 3.943

9.  Tumor-specific expression and alternate splicing of messenger ribonucleic acid encoding activin/transforming growth factor-beta receptors in human pituitary adenomas.

Authors:  J M Alexander; H A Bikkal; N T Zervas; E R Laws; A Klibanski
Journal:  J Clin Endocrinol Metab       Date:  1996-02       Impact factor: 5.958

10.  p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors.

Authors:  M V Ponce-Castañeda; M H Lee; E Latres; K Polyak; L Lacombe; K Montgomery; S Mathew; K Krauter; J Sheinfeld; J Massague
Journal:  Cancer Res       Date:  1995-03-15       Impact factor: 12.701

View more
  36 in total

1.  The p27/Kip1 locus shows no loss of heterozygosity in human pituitary adenomas.

Authors:  J C Wilson; J J Zhu; P M Black
Journal:  J Neurooncol       Date:  1999-08       Impact factor: 4.130

2.  The enhanced peroxidase one step method increases sensitivity for detection of Ki-67 in pituitary tumours.

Authors:  H E Turner; Z Nagy; M M Esiri; J A Wass
Journal:  J Clin Pathol       Date:  1999-08       Impact factor: 3.411

3.  The expression of the F-box protein Skp2 is negatively associated with p27 expression in human pituitary tumors.

Authors:  Madalina Musat; Márta Korbonits; Megan Pyle; Maria Gueorguiev; Blerina Kola; Damian G Morris; Michael Powell; Constantin Dumitrache; Catalina Poiana; Ashley B Grossman
Journal:  Pituitary       Date:  2002       Impact factor: 4.107

4.  Pituitary adenylate cyclase-activating polypeptide inhibits transforming growth factor-beta1-induced apoptosis in a human pituitary adenoma cell line.

Authors:  H Oka; L Jin; E Kulig; B W Scheithauer; R V Lloyd
Journal:  Am J Pathol       Date:  1999-12       Impact factor: 4.307

Review 5.  Pathogenesis of pituitary tumors.

Authors:  Shlomo Melmed
Journal:  Nat Rev Endocrinol       Date:  2011-03-22       Impact factor: 43.330

6.  Determination of cell proliferation using Mcm2 antigen and evaluation of apoptosis and TGF-beta1 expression in GH-secreting or clinically nonfunctioning pituitary adenomas.

Authors:  Cristina Micheletto Dallago; Ligia Maria Barbosa-Coutinho; Nelson Pires Ferreira; Rosalva Meurer; Julia Fernanda Semmelmann Pereira-Lima; Miriam da Costa Oliveira
Journal:  Endocr Pathol       Date:  2010-03       Impact factor: 3.943

Review 7.  Familial pituitary tumor syndromes.

Authors:  Marianne S Elston; Kerrie L McDonald; Roderick J Clifton-Bligh; Bruce G Robinson
Journal:  Nat Rev Endocrinol       Date:  2009-06-30       Impact factor: 43.330

8.  Anterior pituitary adenomas: inherited syndromes, novel genes and molecular pathways.

Authors:  Paraskevi Xekouki; Monalisa Azevedo; Constantine A Stratakis
Journal:  Expert Rev Endocrinol Metab       Date:  2010-09-01

Review 9.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

Review 10.  The molecular biology of pituitary tumors: a personal perspective.

Authors:  Ashley B Grossman
Journal:  Pituitary       Date:  2009       Impact factor: 4.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.